PD23-03 THE IMPACT OF ADDING LOW DOSE ORAL DESMOPRESSIN TO TAMSULOSIN THERAPY FOR TREATMENT OF NOCTURIA SECONDARY TO BENIGN PROSTATIC HYPERPLASIA

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Hormonal Therapy1 Apr 2014PD23-03 THE IMPACT OF ADDING LOW DOSE ORAL DESMOPRESSIN TO TAMSULOSIN THERAPY FOR TREATMENT OF NOCTURIA SECONDARY TO BENIGN PROSTATIC HYPERPLASIA Abul-fotouh Ahmed, Aref Maarouf, Ashraf Shahin, Essam Shalaby, and Ammar Ghobish Abul-fotouh AhmedAbul-fotouh Ahmed More articles by this author , Aref MaaroufAref Maarouf More articles by this author , Ashraf ShahinAshraf Shahin More articles by this author , Essam ShalabyEssam Shalaby More articles by this author , and Ammar GhobishAmmar Ghobish More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1840AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The objective of this multicenter randomized trial was to evaluate the efficacy and safety of adding a low dose oral desmopressin to tamsulosin therapy for treatment of nocturia in patients with benign prostatic hyperplasia (BPH). METHODS Eligible patients with BPH and nocturia ≥ 2/night were randomly allocated to 2 treatment groups: the first group received three months treatment scheme of daily oral dose of tamsulosin OCAS 0.4 mg and desmopressin MELT 60 mcg at bed- time (D/T group) and the second one received tamsulosin OCAS 0.4 mg only (T group). Patients were followed on monthly basis and changes in the parameters from baseline to 3 months after treatments were assessed on I-PSS/QoL questionnaire, 7-day voiding diary, urinalysis, serum sodium, abdominal ultrasonography and uroflowmetry. RESULTS A total of 248 patients were included within the study; 123 patients in combined D/T group and 125 patients in T group. The frequencies of night voids decreased by 64.3% in D/T group compared to 44.6% in T group. In D/T group, but not in T group a significant correlation was found between the severity of nocturia, nocturnal urine volume and response to treatment (p=.000). The first sleep period (FSP), significantly increased from 82.1 to 160.0 minutes and from 83.2 to 123.8 in D/T and T group, respectively; and significant differences between both groups were observed at the end of study (p=.000). I-PSS, QoL score and Qmax were significantly improved with no statistical difference between both groups. Only one patient in D/T group developed clinical hyponatremia. No serious systemic complications were reported for both groups during treatment. CONCLUSIONS The addition of low dose oral desmopressin therapy to an alpha-blocker tamsulosin in LUTS/BPH provides effective treatment for nocturia, especially in severe cases associated with nocturnal polyuria. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e667 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Abul-fotouh Ahmed More articles by this author Aref Maarouf More articles by this author Ashraf Shahin More articles by this author Essam Shalaby More articles by this author Ammar Ghobish More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...